A combination of cancer drugs that can shrink skin cancer tumours in more than half of patients may not be cost-effective for the NHS to supply patients.
A British-led trial has found immune-boosting drugs - ipilimumab and nivolumab - stopped advanced melonoma for nearly a year in 58% of cases.
But the high success rate comes with a high price tag, as ITV News' Health Editor Rachel Younger reports:
How much patients benefit from the new immuno-therapy treatment announced today in the fight against cancer will depend on which drugs suit them best, according to a leading expert.
Speaking to ITV News, Dr Alan Worsley of Cancer Research UK said that patients might respond best to one type of drug or a combination of therapies.
Discovery of an immuno-based therapy has been hailed as a breakthrough in the fight against cancer. We look at other major developmentsRead the full story ›
A pair of cancer drugs can shrink tumours in more than half of patients with an advanced form of skin cancer, according to new research.Read the full story ›
The government is treating the fight against obesity as a priority, as a new report cautions that one in five cancer deaths is caused by it.Read the full story ›
A modified version of the herpes virus has proved a major success in phase III clinical trials.Read the full story ›
A new screening test can detect twice as many ovarian cancers as conventional methods, research has shown.Read the full story ›
A breath test can reveal whether people are likely to have stomach cancer, scientists believe.Read the full story ›
Newly published research has revealed dogs have been found to have 98% reliability rate in sniffing out prostate cancer in men.Read the full story ›
Film star Angelina Jolie has had preventative surgery following signs of ovarian cancer. Here is how you can spot the symptoms early.Read the full story ›